Skip to content
Peptigraph home

AOD-9604 and Tesamorelin Together: What Is Known

AOD-9604 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
HGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[5]GLP-1 & metabolicGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[14]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 3 results, 2 Oct 2026).

We have no sourced data on taking these two together. Ask the prescriber who manages both.
Each component

Side by side

Showing 13 of 14 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.

FieldAOD-9604Tesamorelin
ClassHGH fragment analogGHRH analog
Also calledAODtesa, Egrifta
CategoryGLP-1 & metabolicGrowth hormone
FDA statusNot FDA approved · research chemicalFDA approved (Egrifta)
WADAProhibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.
Anti-doping detection
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeNo published half-life foundPubMed search, 2 Oct 202611 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Evidence strengthAnimal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised11 human (11 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg2 mg, 5 mg, 10 mg, 20 mg
US searches per month18,100 · +31% searches165,000 · +188% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

AOD-9604 vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison
ComparisonAOD-9604 vs Tesamorelin

What people search

  • aod 9604 and tesamorelin together90/mo
  • tesamorelin aod 960450/mo
  • aod 9604 and tesamorelin50/mo
  • tesamorelin aod 9604 stack40/mo
  • tesamorelin and aod960440/mo
  • aod 9604 with tesamorelin40/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  4. 4Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  5. 5Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  6. 6PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  8. 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  9. 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  11. 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  12. 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  13. 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026

Found an error? Report a correction.